IQVIA Holdings Inc.

IQVIA Holdings Inc.

IQVNYSE / NASDAQHealthcareLarge cap

$245.82-$4.73 (-1.9%)

Last close · Data as of Nov 20, 2026

Market cap
$31.2B
P/E
22.9x
EV / EBITDA
13.0x
Revenue
$16.3B
Net margin
8.3%
ROCE
10.6%

+13.2% over the last year

IQVIA Holdings Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-8.2%
3M
-4.0%
6M
+43.3%
1Y
+13.2%
5Y
-8.3%

52-week range

Day change -$4.73 (-1.9%) from $251 to $246 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IQV, bought on each weekday since 2021.

News & filings

What IQVIA Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernCurrent assets are 0.75 times current liabilities.

Strengths (1)

  • Free cash flow was 1.51 times net profit in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read moreShow less

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Sector
Healthcare
Shares outstanding
171.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$31.2B
P/E
22.9x
P/B
4.8x
EV / EBITDA
13.0x
EV / Sales
2.8x
P/S
1.9x
52-week high
$279.36
52-week low
$156.66

Profitability

Operating margin
14.0%
Net margin
8.3%
EBITDA margin
21.2%
ROE
20.9%
ROCE
10.6%
ROA
4.5%
Asset turnover
0.54

Growth

Revenue
$16.3B
Revenue growth, 1Y
5.9%
Revenue CAGR, 3Y
4.2%
Net profit growth, 1Y
-0.9%
Free cash flow
$2.1B

Solvency

Current ratio
0.75
Debt / Equity
2.45
Debt / Assets
0.53
CFO / Net profit
1.95
Cash / Market cap
6.3%

Where the revenue went

Of every $100 of FY2025 revenue, $8 was left as net income.

IQVIA Holdings Inc. income statement flow, FY2025
IQVIA Holdings Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$10.9B
RevenueGross profit$5.4B
Gross profitSelling, general and administrative$2.0B
Gross profitOther operating expenses$1.1B
Gross profitOperating income$2.3B
Operating incomePretax income$1.6B
Operating incomeInterest and other expense$696.0M
Pretax incomeTax and other$231.0M
Pretax incomeNet income$1.4B

Revenue and net profit

Revenue grew 5.9% in FY2025; net profit is the dashed line.

IQVIA Holdings Inc. revenue and net profit by fiscal year
IQVIA Holdings Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$14.4B$1.1B
FY2023$15.0B$1.4B
FY2024$15.4B$1.4B
FY2025$16.3B$1.4B

Cash flows

FY2025: $2.7B from operations, $2.1B free after investment (dashed).

IQVIA Holdings Inc. operating and free cash flow by fiscal year
IQVIA Holdings Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$2.3B$1.6B
FY2023$2.1B$1.5B
FY2024$2.7B$2.1B
FY2025$2.7B$2.1B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$16.3B+5.9%1Y
EBITDA
$3.5B+0.3%1Y
Net profit
$1.4B-0.9%1Y
Cash from operations
$2.7B-2.3%1Y
Free cash flow
$2.1B-3.0%1Y
Revenue CAGR, 3Y
4.2%
Net profit CAGR, 3Y
7.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$16.3B$3.5B$1.4B$2.1B20.9%+5.9%-0.9%

Monthly returns

Month-by-month returns of IQV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$29.9B
Liabilities$23.3B
Equity$6.6B
Paid-in capital$11.4B
Retained earnings$7.4B
Treasury stock$11.4B
Minority interest$127.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IQV highlighted.

P/E against peers

IQV trades at 22.9x earnings against a peer median of 21.3x.

Not shown (no positive earnings and no EV / Sales): Centene Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
IQVIA Holdings Inc.IQVthis company$31.2B22.9x4.8x20.9%13.0x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
GE HealthCare Technologies Inc.GEHC$29.0B13.9x2.8x20.1%9.2x
Biogen Inc.BIIB$29.0B22.4x1.6x7.1%12.5x
ResMed Inc.RMD$28.2B20.1x4.7x23.5%14.5x
DexCom, Inc.DXCM$28.0B33.5x10.2x30.5%21.0x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Peer median—21.3x4.7x21.8%13.5x

Year-to-date ROI

IQV since 1 January, against earlier years.

Historical volatility

IQV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

IQVIA Holdings Inc. operating margin by fiscal year
IQVIA Holdings Inc. operating margin by fiscal year
DateOperating margin
FY202212.7%
FY202313.8%
FY202414.7%
FY202514.0%
LineFY2025
Cost of revenueCost Of Revenue$10.9B
Gross profitGross Profit$5.4B
Operating expensesOperating Expense$3.1B
Selling, general and administrativeSelling General And Administration$2.0B
Depreciation and amortisationDepreciation And Amortization In Income Statement$1.1B
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$1.1B
Total expensesTotal Expenses$14.0B
Pretax incomePretax Income$1.6B

Learn while you research

Academy chapters picked for IQVIA Holdings Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 2.45 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →